Satellos Bioscience Inc. announced preliminary results from a single case study of SAT-3247 treatment in a canine model of Duchenne muscular dystrophy (DMD or Duchenne). This model represents a severe dystrophy that closely reflects disease progression observed in people with DMD. SAT-3247 is in development as a novel regenerative medicine approach to treating DMD.

These data were presented at the Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference this past weekend. After treatment with SAT-3247 the animals showed an increase in Regenerative Index (RI), a measure of the number of newly regenerated muscle fibers versus the number of damaged and dying muscle fibers.